224 related articles for article (PubMed ID: 27571745)
21. Inhibition of osteoclast bone resorption activity through osteoprotegerin-induced damage of the sealing zone.
Song R; Gu J; Liu X; Zhu J; Wang Q; Gao Q; Zhang J; Cheng L; Tong X; Qi X; Yuan Y; Liu Z
Int J Mol Med; 2014 Sep; 34(3):856-62. PubMed ID: 25017214
[TBL] [Abstract][Full Text] [Related]
22. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
[TBL] [Abstract][Full Text] [Related]
23. Differentiation of osteoprogenitor cells is affected by trauma-haemorrhage.
Neunaber C; Yesilkaya P; Pütz C; Krettek C; Hildebrand F
Injury; 2013 Oct; 44(10):1279-84. PubMed ID: 23773407
[TBL] [Abstract][Full Text] [Related]
24. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
Ozaki Y; Koide M; Furuya Y; Ninomiya T; Yasuda H; Nakamura M; Kobayashi Y; Takahashi N; Yoshinari N; Udagawa N
PLoS One; 2017; 12(9):e0184904. PubMed ID: 28937990
[TBL] [Abstract][Full Text] [Related]
25. Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling.
Koide M; Kinugawa S; Ninomiya T; Mizoguchi T; Yamashita T; Maeda K; Yasuda H; Kobayashi Y; Nakamura H; Takahashi N; Udagawa N
J Bone Miner Res; 2009 Aug; 24(8):1469-80. PubMed ID: 19292614
[TBL] [Abstract][Full Text] [Related]
26. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
[TBL] [Abstract][Full Text] [Related]
27. Osteoprotegerin influences the bone resorption activity of osteoclasts.
Fu YX; Gu JH; Zhang YR; Tong XS; Zhao HY; Yuan Y; Liu XZ; Bian JC; Liu ZP
Int J Mol Med; 2013 Jun; 31(6):1411-7. PubMed ID: 23563320
[TBL] [Abstract][Full Text] [Related]
28. Effect of gallium nitrate on the expression of osteoprotegerin and receptor activator of nuclear factor‑κB ligand in osteoblasts in vivo and in vitro.
Li J; Wang GB; Feng X; Zhang J; Fu Q
Mol Med Rep; 2016 Jan; 13(1):769-77. PubMed ID: 26647856
[TBL] [Abstract][Full Text] [Related]
29. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
[TBL] [Abstract][Full Text] [Related]
30. Osthole enhances the bone mass of senile osteoporosis and stimulates the expression of osteoprotegerin by activating β-catenin signaling.
Jin ZX; Liao XY; Da WW; Zhao YJ; Li XF; Tang DZ
Stem Cell Res Ther; 2021 Feb; 12(1):154. PubMed ID: 33640026
[TBL] [Abstract][Full Text] [Related]
31. The prenyl group contributes to activities of phytoestrogen 8-prenynaringenin in enhancing bone formation and inhibiting bone resorption in vitro.
Ming LG; Lv X; Ma XN; Ge BF; Zhen P; Song P; Zhou J; Ma HP; Xian CJ; Chen KM
Endocrinology; 2013 Mar; 154(3):1202-14. PubMed ID: 23389955
[TBL] [Abstract][Full Text] [Related]
32. Increased OPG/RANKL ratio in the conditioned medium of soybean-treated osteoblasts suppresses RANKL-induced osteoclast differentiation.
Park K; Ju WC; Yeo JH; Kim JY; Seo HS; Uchida Y; Cho Y
Int J Mol Med; 2014 Jan; 33(1):178-84. PubMed ID: 24248634
[TBL] [Abstract][Full Text] [Related]
33. Puerarin prevents bone loss in ovariectomized mice and inhibits osteoclast formation in vitro.
Yuan SY; Sheng T; Liu LQ; Zhang YL; Liu XM; Ma T; Zheng H; Yan Y; Ishimi Y; Wang XX
Chin J Nat Med; 2016 Apr; 14(4):265-269. PubMed ID: 27114313
[TBL] [Abstract][Full Text] [Related]
34. WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling.
Chen C; Qin Y; Fang JP; Ni XY; Yao J; Wang HY; Ding K
Acta Pharmacol Sin; 2015 Sep; 36(9):1053-64. PubMed ID: 26299951
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.
Kim YH; Kim GS; Jeong-Hwa B
Exp Mol Med; 2002 May; 34(2):145-51. PubMed ID: 12085990
[TBL] [Abstract][Full Text] [Related]
36. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
37. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
Lee SK; Lorenzo JA
Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
[TBL] [Abstract][Full Text] [Related]
38. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice.
Piemontese M; Xiong J; Fujiwara Y; Thostenson JD; O'Brien CA
Am J Physiol Endocrinol Metab; 2016 Sep; 311(3):E587-93. PubMed ID: 27460899
[TBL] [Abstract][Full Text] [Related]
39. Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption.
Sasaki T
Microsc Res Tech; 2003 Aug; 61(6):483-95. PubMed ID: 12879416
[TBL] [Abstract][Full Text] [Related]
40. Rosmarinic acid exerts an antiosteoporotic effect in the RANKL-induced mouse model of bone loss by promotion of osteoblastic differentiation and inhibition of osteoclastic differentiation.
Lee JW; Asai M; Jeon SK; Iimura T; Yonezawa T; Cha BY; Woo JT; Yamaguchi A
Mol Nutr Food Res; 2015 Mar; 59(3):386-400. PubMed ID: 25380345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
